These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20209052)

  • 1. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism.
    Yuen DA; Connelly KA; Advani A; Liao C; Kuliszewski MA; Trogadis J; Thai K; Advani SL; Zhang Y; Kelly DJ; Leong-Poi H; Keating A; Marsden PA; Stewart DJ; Gilbert RE
    PLoS One; 2010 Mar; 5(3):e9543. PubMed ID: 20209052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis.
    Yuen DA; Connelly KA; Zhang Y; Advani SL; Thai K; Kabir G; Kepecs D; Spring C; Smith C; Batruch I; Kosanam H; Advani A; Diamandis E; Marsden PA; Gilbert RE
    Stem Cells; 2013 Nov; 31(11):2408-19. PubMed ID: 23922321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease.
    Rota C; Morigi M; Cerullo D; Introna M; Colpani O; Corna D; Capelli C; Rabelink TJ; Leuning DG; Rottoli D; Benigni A; Zoja C; Remuzzi G
    Stem Cell Res Ther; 2018 Aug; 9(1):220. PubMed ID: 30107860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis.
    Uchimura H; Marumo T; Takase O; Kawachi H; Shimizu F; Hayashi M; Saruta T; Hishikawa K; Fujita T
    J Am Soc Nephrol; 2005 Apr; 16(4):997-1004. PubMed ID: 15744001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats.
    Alfarano C; Roubeix C; Chaaya R; Ceccaldi C; Calise D; Mias C; Cussac D; Bascands JL; Parini A
    Cell Transplant; 2012; 21(9):2009-19. PubMed ID: 22525800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Marrow-Derived Mesenchymal Stem Cells and Their Conditioned Medium Attenuate Fibrosis in an Irreversible Model of Unilateral Ureteral Obstruction.
    da Silva AF; Silva K; Reis LA; Teixeira VP; Schor N
    Cell Transplant; 2015; 24(12):2657-66. PubMed ID: 25695732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice.
    Ninichuk V; Gross O; Segerer S; Hoffmann R; Radomska E; Buchstaller A; Huss R; Akis N; Schlöndorff D; Anders HJ
    Kidney Int; 2006 Jul; 70(1):121-9. PubMed ID: 16723981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
    Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
    J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditioned mesenchymal stem cells attenuate progression of chronic kidney disease through inhibition of epithelial-to-mesenchymal transition and immune modulation.
    Chang JW; Tsai HL; Chen CW; Yang HW; Yang AH; Yang LY; Wang PS; Ng YY; Lin TL; Lee OK
    J Cell Mol Med; 2012 Dec; 16(12):2935-49. PubMed ID: 22862802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paracrine Activation of the Wnt/β-Catenin Pathway by Bone Marrow Stem Cell Attenuates Cisplatin-Induced Kidney Injury.
    Jiao X; Cai J; Yu X; Ding X
    Cell Physiol Biochem; 2017; 44(5):1980-1994. PubMed ID: 29237155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal cells protect against acute tubular injury via an endocrine effect.
    Bi B; Schmitt R; Israilova M; Nishio H; Cantley LG
    J Am Soc Nephrol; 2007 Sep; 18(9):2486-96. PubMed ID: 17656474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial.
    Yuen DA; Kepecs DM; Zhang Y; Advani S; Thai K; Connelly KA; Gilbert RE
    Can J Kidney Health Dis; 2015; 2():44. PubMed ID: 26568839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fate alteration of bone marrow-derived macrophages ameliorates kidney fibrosis in murine model of unilateral ureteral obstruction.
    Yang Y; Feng X; Liu X; Wang Y; Hu M; Cao Q; Zhang Z; Zhao L; Zhang J; Guo R; Wang H; Qiao X; Wang L; Zheng G
    Nephrol Dial Transplant; 2019 Oct; 34(10):1657-1668. PubMed ID: 30590718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin delta as an antifibrotic agent in the remnant kidney rat: a possible role for transforming growth factor beta and hepatocyte growth factor.
    De Beuf A; D'Haese PC; Verhulst A
    Nephron Exp Nephrol; 2010; 115(3):e46-59. PubMed ID: 20424483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy.
    Huuskes BM; Wise AF; Cox AJ; Lim EX; Payne NL; Kelly DJ; Samuel CS; Ricardo SD
    FASEB J; 2015 Feb; 29(2):540-53. PubMed ID: 25395452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
    Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
    Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis.
    Nakamura T; Obata JE; Onitsuka M; Shimada Y; Yoshida Y; Kawachi H; Shimizu F
    Nephron; 2000 Nov; 86(3):315-26. PubMed ID: 11096289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of protease therapy in the remnant kidney model of progressive renal failure.
    Sebekova K; Paczek L; Dämmrich J; Ling H; Spustova V; Gaciong Z; Heidland A
    Miner Electrolyte Metab; 1997; 23(3-6):291-5. PubMed ID: 9387136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats.
    Broekema M; Harmsen MC; van Luyn MJ; Koerts JA; Petersen AH; van Kooten TG; van Goor H; Navis G; Popa ER
    J Am Soc Nephrol; 2007 Jan; 18(1):165-75. PubMed ID: 17135399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Wharton's jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells.
    Du T; Zou X; Cheng J; Wu S; Zhong L; Ju G; Zhu J; Liu G; Zhu Y; Xia S
    Stem Cell Res Ther; 2013 Jun; 4(3):59. PubMed ID: 23734757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.